Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

Investing.com -- Edwards Lifesciences (NYSE:EW) stock rose 4.5% following the presentation of new data showing long-term benefits and valve performance of its SAPIEN 3 TAVR.

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...

Facing an upcoming surgical procedure often brings stress and anxiety, but not for Della de Corse. When she learned she would ...

Researchers support limiting these surgeries to centers that do the most cases, though true high-volume hospitals remain rare ...

Edwards Lifesciences Corp. (($EW)) announced an update on their ongoing clinical study. Edwards Lifesciences Corp. is collaborating with World ...

Edwards Lifesciences remains a market leader in transcatheter heart valve technologies, with strong secular tailwinds and ...

Managing perioperative opioid risks, improving detection of peripheral artery disease and surgical management of hard-to-treat gastrointestinal cancers, were among the topics UCSF surgeons, clinicians ...

Using a catheter to repair or replace a valve is a fairly recent breakthrough in the world of interventional cardiology. Early on, it was a procedure reserved largely for patients with a faulty aortic ...

Expanding your horizons and considering neglected sectors can help you identify bargain opportunities while defending your ...